Skip to content
Calculator

Peptide trials recruiting now

Every study on ClinicalTrials.gov that is recruiting, not yet recruiting, or enrolling by invitation and tests a peptide in our encyclopedia, read from the registry on 2026-11-18. For each one: its phase, whether people are randomized, who is blinded, what the peptide is compared with, how many people it plans to enroll, its primary outcome, where it runs and who sponsors it. A registered trial is a plan, not a result: it says what researchers will measure, not what the peptide does. Whether you can join is decided by each study's own eligibility rules and its listed contacts on ClinicalTrials.gov. Nothing here is medical advice, and Grey Peptides sells nothing.

1,868
Open studies
202
Peptides with one or more
209
Testing unapproved peptides
557
Placebo-controlled
583
With a US site

322 studies listed in full across 96 peptides

Peptides not approved anywhere (68)

Peptides with no approval for any use in any country we have found, where a registered trial is the strongest evidence still to come. Every open study is listed.

Eloralintide 15 open studies, 11 placebo-controlled

Glutathione 12 open studies, 6 placebo-controlled

  • S-Acetyl Glutathione and Performance Recovery in Soccer

    Not yet recruiting NCT07690124 · No phase · Randomized, triple-blind, vs placebo · 20 people

    Primary outcome
    Change in creatine kinase levels (Day 1, day 7, day 9, day 10 and day 11) +12 more
    Where
    Greece
    Sponsor (as registered)
    University of Thessaly
    Dates
    Start 2026-09-01 · record updated 2026-07-08
  • GAIP ASD Research Study

    Recruiting NCT07622316 · Phase 1 · Randomized, double-blind, vs an active drug · 100 people

    Primary outcome
    Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6 (Baseline and Month 6)
    Where
    United States
    Sponsor (as registered)
    Greater Atlanta Integrative Pediatrics
    Dates
    Start 2026-06-01 · record updated 2026-06-03
  • Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

    Recruiting NCT07572890 · Phase 1 · Randomized, single-blind, vs placebo and an active drug · 100 people

    Primary outcome
    Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) (Baseline to Month 6) +1 more
    Where
    United States
    Sponsor (as registered)
    Adia Med of Winter Park LLC
    Dates
    Start 2026-05-18 · record updated 2026-06-17
  • Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study

    Recruiting NCT07304440 · Phase 1 · Randomized, single-blind, vs an active drug · 100 people

    Primary outcome
    Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6 (Baseline and Month 6)
    Where
    United States
    Sponsor (as registered)
    Adia Med of Winter Park LLC
    Dates
    Start 2026-05-01 · record updated 2026-09-22
  • Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma

    Not yet recruiting NCT07448415 · Phase 2 / Phase 3 · Randomized, open label, vs an active drug · 42 people

    Primary outcome
    compare reduction of Melasma Area and Severity Index (MASI) score in any treatment modalities (From baseline to 12 weeks)
    Where
    Not listed
    Sponsor (as registered)
    Assiut University
    Dates
    Start 2026-02 · record updated 2026-03-04
  • Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet

    Recruiting NCT07379216 · No phase · Randomized, double-blind, vs placebo · 30 people

    Primary outcome
    The change of skin tone (Change from Baseline skin tone at 12 weeks) +2 more
    Where
    Taiwan
    Sponsor (as registered)
    TCI Co., Ltd.
    Dates
    Start 2026-01-24 · record updated 2026-02-04
  • Gingival Hyperpigmentation Treatment

    Recruiting NCT07595705 · Phase 2 · Randomized, open label, vs an active drug · 30 people

    Primary outcome
    Degree of gingival pigmentation by Takashi index (Hanioka et al., 2005) (baseline: before surgery/injection (day1), after 1 mon ,3 mon ,6 mon and 9 month) +1 more
    Where
    Egypt
    Sponsor (as registered)
    Cairo University
    Dates
    Start 2025-08-01 · record updated 2026-05-19
  • Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

    Recruiting NCT06922669 · No phase · Randomized, open label, vs an active drug · 232 people

    Primary outcome
    Improvement of DILI on the second week (2 weeks)
    Where
    China
    Sponsor (as registered)
    General Hospital of Shenyang Military Region
    Dates
    Start 2025-06-24 · record updated 2025-12-18
  • Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

    Recruiting NCT06896422 · Phase 1 · Randomized, open label, vs placebo · 80 people

    Primary outcome
    Progression-Free Survival (PFS) (From randomization until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.") +1 more
    Where
    China
    Sponsor (as registered)
    The First Affiliated Hospital of Zhengzhou University
    Dates
    Start 2025-06-01 · record updated 2025-08-07
  • Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma

    Recruiting NCT07202156 · No phase · Randomized, single-blind, no comparator listed · 35 people

    Primary outcome
    percentage reduction in hemi-MASI (From enrollment to the end of treatment at 8 weeks, and 4&12 weeks after the final intervention)
    Where
    China
    Sponsor (as registered)
    The First Affiliated Hospital with Nanjing Medical University
    Dates
    Start 2024-10-20 · record updated 2025-11-25
  • Prevent Cardiac Surgery Associated AKI Trial

    Recruiting NCT06620523 · Phase 2 · Randomized, triple-blind, vs placebo and an active drug · 242 people

    Primary outcome
    AKI incidence reduction (28 days) +1 more
    Where
    United States
    Sponsor (as registered)
    George Washington University
    Dates
    Start 2024-07-18 · record updated 2026-10-14
  • Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

    Recruiting NCT05266417 · Phase 2 · Randomized, triple-blind, vs placebo · 56 people

    Primary outcome
    Verbal Fluency (24 Weeks)
    Where
    United States
    Sponsor (as registered)
    Gateway Institute for Brain Research
    Dates
    Start 2022-02-07 · record updated 2026-07-22

UBT251 11 open studies, 6 placebo-controlled

Cagrilintide 10 open studies, 10 placebo-controlled

HRS-9531 9 open studies, 6 placebo-controlled

Maridebart cafraglutide 9 open studies, 3 placebo-controlled

Pentixafor 8 open studies

Survodutide 8 open studies, 6 placebo-controlled

Avexitide 7 open studies, 2 placebo-controlled

  • Hypothalamic GLP-1 Response in Healthy Weight and Obesity

    Recruiting NCT07854886 · No phase · Randomized, double-blind, no comparator listed · 60 people

    Primary outcome
    Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline (During the MRI scan on three test days) +1 more
    Where
    Denmark
    Sponsor (as registered)
    University of Copenhagen
    Dates
    Start 2026-10-01 · record updated 2026-11-02
  • The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

    Not yet recruiting NCT06972407 · Phase 2 · Randomized, open label, vs placebo and an active drug · 80 people

    Primary outcome
    Change in fasting glucose (Change in average glucose concentration between -30 min and 0 min of each study day (saline day vs. exendin 9-39 day)) +1 more
    Where
    United States
    Sponsor (as registered)
    Mayo Clinic
    Dates
    Start 2026-10-01 · record updated 2026-01-30
  • Islet Function in Gestational Diabetes

    Recruiting NCT07806695 · Phase 1 · Not randomized, open label, no comparator listed · 90 people

    Primary outcome
    G50 (During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.)
    Where
    United States
    Sponsor (as registered)
    Mayo Clinic
    Dates
    Start 2026-09 · record updated 2026-09-08
  • The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

    Recruiting NCT06967558 · Phase 2 · Randomized, open label, vs placebo and an active drug · 60 people

    Primary outcome
    Alpha-cell responsivity to glucose as measured by G50 (0-240 minutes) +1 more
    Where
    United States
    Sponsor (as registered)
    Mayo Clinic
    Dates
    Start 2025-11-01 · record updated 2025-12-15
  • The Effects of Bariatric Surgeries on Glucose Metabolism

    Recruiting NCT02823665 · Early phase 1 · Randomized, single-blind, no comparator listed · 200 people

    Primary outcome
    Insulin levels measured after nutrient ingestion (Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.)
    Where
    United States
    Sponsor (as registered)
    The University of Texas Health Science Center at San Antonio
    Dates
    Start 2015-07 · record updated 2025-09-09
  • Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

    Recruiting NCT00992901 · Early phase 1 · Not randomized, open label, no comparator listed · 160 people

    Primary outcome
    Gut hormones and neural signaling contribution to insulin secretion rate and glucose tolerance (Each study of the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.)
    Where
    United States
    Sponsor (as registered)
    The University of Texas Health Science Center at San Antonio
    Dates
    Start 2009-10 · record updated 2025-09-09
  • Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

    Recruiting NCT01803451 · Early phase 1 · Not randomized, single-blind, no comparator listed · 80 people

    Primary outcome
    The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated (up to 1 year (10 sessions))
    Where
    United States
    Sponsor (as registered)
    The University of Texas Health Science Center at San Antonio
    Dates
    Start 2005-11 · record updated 2025-09-09

AZD6234 6 open studies, 4 placebo-controlled

Enicepatide 6 open studies, 5 placebo-controlled

GIP 6 open studies, 4 placebo-controlled

FAP-2286 5 open studies

  • FAP PET/CT for Staging Patients With Breast Cancer

    Not yet recruiting NCT07523607 · Phase 2 · Single group, open label, no comparator listed · 65 people

    Primary outcome
    Number of patients with nodal and distant metastases detected by [⁶⁸Ga]Ga-FAP-2286 PET/CT at baseline (pre-treatment staging) (Baseline (pre-treatment). Inclusion period 1 year.) +1 more
    Where
    Not listed
    Sponsor (as registered)
    Odense University Hospital
    Dates
    Start 2026-06-01 · record updated 2026-04-13
  • Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

    Not yet recruiting NCT07434180 · Phase 2 · Single group, open label, no comparator listed · 20 people

    Primary outcome
    Overall Response Rate (ORR) (From start of treatment until end of follow-up (study completion- 2 years after the last patient has commenced treatment))
    Where
    Australia
    Sponsor (as registered)
    Peter MacCallum Cancer Centre, Australia
    Dates
    Start 2026-06 · record updated 2026-02-25
  • Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

    Recruiting NCT07144085 · Phase 1 · Single group, open label, no comparator listed · 30 people

    Primary outcome
    Count of participants with treatment-emergent adverse events (Up to 3 days) +4 more
    Where
    China
    Sponsor (as registered)
    Yi Tian
    Dates
    Start 2025-09-11 · record updated 2026-04-03
  • A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

    Recruiting NCT04939610 · Phase 1 / Phase 2 · Not randomized, open label, no comparator listed · 222 people

    Primary outcome
    Phase 1: Dose-limiting toxicity (DLTs) (From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)) +6 more
    Where
    Australia, Canada, France, Italy, Spain, United States
    Sponsor (as registered)
    Novartis Pharmaceuticals
    Dates
    Start 2021-07-30 · record updated 2026-07-24
  • Imaging of Solid Tumors Using FAP-2286

    Recruiting NCT04621435 · Phase 1 · Not randomized, open label, no comparator listed · 191 people

    Primary outcome
    Count of participants with treatment-emergent adverse events (Until end of day on the day of the injection (1 day total)) +4 more
    Where
    United States
    Sponsor (as registered)
    Thomas Hope
    Dates
    Start 2020-12-14 · record updated 2026-06-04

Lutropin alfa 5 open studies, 1 placebo-controlled

NAD+ 5 open studies, 4 placebo-controlled

Petrelintide 5 open studies, 4 placebo-controlled

CagriSema 4 open studies, 2 placebo-controlled

Amylin 3 open studies, 3 placebo-controlled

  • Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    Recruiting NCT07506369 · No phase · Randomized, double-blind, vs placebo and an active drug · 18 people

    Primary outcome
    Food intake (300 to 330 minutes)
    Where
    Denmark
    Sponsor (as registered)
    University Hospital, Gentofte, Copenhagen
    Dates
    Start 2026-04 · record updated 2026-04-01
  • Amylin-Induced Migraine Attacks Without Aura

    Not yet recruiting NCT07340788 · No phase · Randomized, quadruple-blind, vs placebo · 21 people

    Primary outcome
    Incidence of migraine attacks without aura (12 hours)
    Where
    Denmark
    Sponsor (as registered)
    Danish Headache Center
    Dates
    Start 2026-02 · record updated 2026-01-14
  • Hypersensitivity to Amylin in Post-Traumatic Headache

    Not yet recruiting NCT07340775 · No phase · Randomized, quadruple-blind, vs placebo · 21 people

    Primary outcome
    Incidence of migraine-like headache (12 hours)
    Where
    Denmark
    Sponsor (as registered)
    Danish Headache Center
    Dates
    Start 2026-02 · record updated 2026-01-14

Angiotensin-(1-7) 3 open studies, 3 placebo-controlled

  • Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

    Recruiting NCT06482853 · Early phase 1 · Randomized, double-blind, vs placebo · 52 people

    Primary outcome
    Change in Muscle Sympathetic Nerve Burst Rate (120 minutes) +1 more
    Where
    United States
    Sponsor (as registered)
    Milton S. Hershey Medical Center
    Dates
    Start 2025-01-23 · record updated 2026-09-24
  • Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

    Recruiting NCT06282965 · Phase 1 / Phase 2 · Randomized, triple-blind, vs placebo · 90 people

    Primary outcome
    Number of participants with adverse events (At 21 days) +1 more
    Where
    United States
    Sponsor (as registered)
    University of Arizona
    Dates
    Start 2024-05-28 · record updated 2026-08-11
  • Metabolic Effects of Angiotensin-(1-7)

    Recruiting NCT02646475 · Phase 1 · Randomized, double-blind, vs placebo · 26 people

    Primary outcome
    Whole-Body Insulin Sensitivity (steady-state (time 90 to 120 minutes) during hyperinsulinemic-euglycemic clamp)
    Where
    United States
    Sponsor (as registered)
    Vanderbilt University
    Dates
    Start 2016-02 · record updated 2026-05-22

Kisspeptin-54 3 open studies

  • Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

    Recruiting NCT07224490 · Phase 1 · Single group, open label, no comparator listed · 40 people

    Primary outcome
    Difference in mean luteinizing hormone (LH) amplitude between cases and controls (Day of study visit (one to two hours))
    Where
    United States
    Sponsor (as registered)
    Stephanie B. Seminara, MD
    Dates
    Start 2026-03-10 · record updated 2026-07-13
  • Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

    Recruiting NCT07224438 · Phase 2 · Single group, open label, no comparator listed · 20 people

    Primary outcome
    Change of luteinizing hormone (LH) pulse amplitude (2 weeks)
    Where
    United States
    Sponsor (as registered)
    Stephanie B. Seminara, MD
    Dates
    Start 2025-12-09 · record updated 2026-07-13
  • Kisspeptin Administration Subcutaneously to Patients With IHH

    Recruiting NCT05896293 · Phase 2 · Single group, open label, no comparator listed · 36 people

    Primary outcome
    Average change in luteinizing hormone (LH) pulse amplitude (2 weeks)
    Where
    United States
    Sponsor (as registered)
    Stephanie B. Seminara, MD
    Dates
    Start 2023-02-03 · record updated 2026-07-13

Nesiritide 3 open studies, 2 placebo-controlled

  • rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)

    Not yet recruiting NCT07617675 · Phase 4 · Randomized, quadruple-blind, vs placebo · 694 people

    Primary outcome
    Incidence of acute kidney injury (AKI) within 7 days postoperatively, diagnosed per KDIGO criteria (Within 7 days after surgery, or until hospital discharge if earlier)
    Where
    China
    Sponsor (as registered)
    China National Center for Cardiovascular Diseases
    Dates
    Start 2026-05-01 · record updated 2026-06-01
  • Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery

    Not yet recruiting NCT07086287 · No phase · Randomized, single-blind, no comparator listed · 120 people

    Primary outcome
    the incidence of renal replacement therapy (From enrollment to discharge: at enrollment, the maintenance dose of rhBNP is 0.0075-0.01ug/kg/min, after 1 hour, 24 hours, 48 hours, and 72 hours post-medication.)
    Where
    China
    Sponsor (as registered)
    The First Affiliated Hospital of Anhui Medical University
    Dates
    Start 2025-08-01 · record updated 2025-07-25
  • Nesiritide in Hypertension

    Recruiting NCT02608996 · Phase 1 / Phase 2 · Randomized, single-blind, vs placebo and an active drug · 15 people

    Primary outcome
    Changes in blood pressure (BP) (48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.)
    Where
    Norway
    Sponsor (as registered)
    Oslo University Hospital
    Dates
    Start 2015-12 · record updated 2018-01-03

    This registry record has not been updated since 2018-01-03, so its "recruiting" status may be out of date.

Olatorepatide 3 open studies, 3 placebo-controlled

Pegozafermin 3 open studies, 2 placebo-controlled

Teverelix 3 open studies, 2 placebo-controlled

VK2735 3 open studies, 3 placebo-controlled

  • Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

    Recruiting NCT07868939 · Phase 3 · Randomized, double-blind, vs placebo · 560 people

    Primary outcome
    Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily (68 weeks)
    Where
    United States
    Sponsor (as registered)
    Viking Therapeutics, Inc.
    Dates
    Start 2026-11 · record updated 2026-11-16
  • Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

    Recruiting NCT07868835 · Phase 3 · Randomized, double-blind, vs placebo · 560 people

    Primary outcome
    Percentage change in body weight for participants receiving VK2735 orally once daily (68 weeks)
    Where
    United States
    Sponsor (as registered)
    Viking Therapeutics, Inc.
    Dates
    Start 2026-11 · record updated 2026-11-16
  • A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

    Recruiting NCT07838740 · Phase 1 · Randomized, double-blind, vs placebo · 270 people

    Primary outcome
    Evaluate the Safety and Tolerability VK2735 (33 weeks)
    Where
    United States
    Sponsor (as registered)
    Viking Therapeutics, Inc.
    Dates
    Start 2025-11-18 · record updated 2026-09-24

Adrenomedullin 2 open studies, 2 placebo-controlled

  • Selective Activation of the Adrenomedullin Receptors in Migraine

    Recruiting NCT07451769 · No phase · Randomized, quadruple-blind, vs placebo · 26 people

    Primary outcome
    Incidence of migraine attacks (Assessed from baseline to 12 hours post-infusion of adrenomedullin or placebo)
    Where
    Denmark
    Sponsor (as registered)
    Danish Headache Center
    Dates
    Start 2026-03-12 · record updated 2026-08-28
  • Hypersensitivity to Adrenomedullin in Post-Traumatic Headache

    Recruiting NCT07059546 · No phase · Randomized, quadruple-blind, vs placebo · 21 people

    Primary outcome
    Incidence of headache with migraine-like features (12 hours)
    Where
    Denmark
    Sponsor (as registered)
    Danish Headache Center
    Dates
    Start 2025-08-01 · record updated 2025-07-30

Bimagrumab 2 open studies, 1 placebo-controlled

  • A Study of Bimagrumab in Participants With HFpEF

    Not yet recruiting NCT07920887 · Phase 2 · Randomized, double-blind, vs placebo · 540 people

    Primary outcome
    Change from Baseline in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) (Baseline, Week 52)
    Where
    Hungary, Italy, Poland, United States
    Sponsor (as registered)
    Eli Lilly and Company
    Dates
    Start 2026-11 · record updated 2026-11-06
  • Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

    Recruiting NCT05933499 · Phase 2 · Randomized, quadruple-blind, vs an active drug · 63 people

    Primary outcome
    Change in number of kilograms of lean mass by dual-energy x-ray absorptiometry (52 weeks)
    Where
    United States
    Sponsor (as registered)
    Massachusetts General Hospital
    Dates
    Start 2025-11-05 · record updated 2026-03-27

Bofanglutide 2 open studies

BPC-157 2 open studies, 2 placebo-controlled

  • Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery

    Not yet recruiting NCT07803250 · Phase 1 · Randomized, quadruple-blind, vs placebo · 30 people

    Primary outcome
    Shoulder Strength (Baseline, 12 weeks, and 5 months post operatively)
    Where
    United States
    Sponsor (as registered)
    University of Arkansas
    Dates
    Start 2027-01-01 · record updated 2026-09-03
  • BPC 157 for Acute Hamstring Muscle Strain Repair

    Recruiting NCT07437547 · Phase 2 · Randomized, quadruple-blind, vs placebo · 120 people

    Primary outcome
    Time to return to unrestricted sport participation (days) (8 Weeks) +1 more
    Where
    China
    Sponsor (as registered)
    Hudson Biotech
    Dates
    Start 2026-02-02 · record updated 2026-02-27

C-peptide 2 open studies, 1 placebo-controlled

Efruxifermin 2 open studies, 2 placebo-controlled

GLP-1 2 open studies, 1 placebo-controlled

  • Hypothalamic GLP-1 Response in Healthy Weight and Obesity

    Recruiting NCT07854886 · No phase · Randomized, double-blind, no comparator listed · 60 people

    Primary outcome
    Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline (During the MRI scan on three test days) +1 more
    Where
    Denmark
    Sponsor (as registered)
    University of Copenhagen
    Dates
    Start 2026-10-01 · record updated 2026-11-02
  • The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

    By invitation NCT07687589 · No phase · Randomized, double-blind, vs placebo and an active drug · 14 people

    Primary outcome
    Change in GLP-1 induced nausea intensity (From enrollment to the end of treatment at up to 12 weeks.)
    Where
    Denmark
    Sponsor (as registered)
    University of Copenhagen
    Dates
    Start 2026-05-19 · record updated 2026-07-07

Pentixather 2 open studies

  • A Safety Study of 212Pb-Pentixather Radioligand Therapy

    Not yet recruiting NCT05557708 · Early phase 1 · Single group, open label, no comparator listed · 20 people

    Primary outcome
    Determine the recommended phase 2 dose of 212-Lead Pentixather (3 months)
    Where
    United States
    Sponsor (as registered)
    Yusuf Menda
    Dates
    Start 2026-07-01 · record updated 2025-07-08
  • [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

    Recruiting NCT06132737 · Phase 1 / Phase 2 · Single group, open label, no comparator listed · 15 people

    Primary outcome
    Incidence, severity and relationship of (S)AEs (graded in severity according to NCI CTCAE version 5.0) (From screening until including the last follow-up visit. SAEs occuring after the end of the study should only be reported to Pentixapharm if the Investigator considers there is a causal relationship with the study drug.)
    Where
    Germany
    Sponsor (as registered)
    Pentixapharm AG
    Dates
    Start 2023-11-07 · record updated 2026-06-05

Pramlintide 2 open studies, 2 placebo-controlled

Retatrutide 2 open studies, 2 placebo-controlled

SAR-bisPSMA 2 open studies

Apraglutide 1 open study, 1 placebo-controlled

Balixafortide 1 open study

Bradykinin 1 open study

  • Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated Angioedema

    Recruiting NCT04763577 · No phase · Observational (no drug assigned by the study) · 243 people

    Primary outcome
    Prognostic Value of Bradykinin degradating enzymes (Association between the activity of kinin-degrading enzymes (ECA, APP, DPP4) measured by enzyme methods, expressed in tertiles, and relapse at 6 months.)
    Where
    France
    Sponsor (as registered)
    University Hospital, Grenoble
    Dates
    Start 2021-10-27 · record updated 2025-02-25

Canvuparatide 1 open study, 1 placebo-controlled

Catestatin 1 open study, 1 placebo-controlled

  • Assessment of Serum Catestatin Level in Acne Vulgaris Patients

    Recruiting NCT07054398 · No phase · Randomized, open label, vs placebo and an active drug · 60 people

    Primary outcome
    Evalaute serum level of Catestatin in acne patient (12 weeks) +1 more
    Where
    Egypt
    Sponsor (as registered)
    Aswan University
    Dates
    Start 2025-01-10 · record updated 2025-07-08

CGRP 1 open study, 1 placebo-controlled

CNP 1 open study

DOTA-EB-TATE 1 open study

  • 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

    Not yet recruiting NCT06991738 · Phase 1 / Phase 2 · Single group, open label, no comparator listed · 18 people

    Primary outcome
    To determine the optimal dose of 177Lu-DOTA-EB-TATE that is both safe and shows sufficient efficacy for treatment of metastatic HTC based on TITE-BOIN12 design of phase 1/2 clinical trial [1, 2]. (8-12 weeks) +2 more
    Where
    United States
    Sponsor (as registered)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Dates
    Start 2026-11-22 · record updated 2026-11-17

ECC5004 1 open study, 1 placebo-controlled

Endothelin-1 1 open study

  • Prenatal Aspirin and Postpartum Vascular Function

    Recruiting NCT05653973 · Early phase 1 · Single group, open label, no comparator listed · 60 people

    Primary outcome
    microvascular endothelial function (at the study visit, an average of 4 hours) +1 more
    Where
    United States
    Sponsor (as registered)
    Anna Stanhewicz, PhD
    Dates
    Start 2023-01-03 · record updated 2025-05-31

Gastrin 1 open study

  • Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

    Recruiting NCT03746769 · Phase 1 / Phase 2 · Single group, open label, no comparator listed · 20 people

    Primary outcome
    Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% ("complete response") (1 year post transplant (6 months after second course of Gastrin))
    Where
    United States
    Sponsor (as registered)
    City of Hope Medical Center
    Dates
    Start 2019-05-29 · record updated 2026-10-15

GHK-Cu 1 open study, 1 placebo-controlled

  • Topical GHK-Cu Gel for Acute Skin Wound Healing

    Recruiting NCT07437586 · Phase 2 · Randomized, quadruple-blind, vs placebo · 60 people

    Primary outcome
    Time to complete re-epithelialization (days) of each wound, defined as 100% epithelial coverage without drainage, confirmed by blinded clinical assessment and standardized photography. (21 Days)
    Where
    China
    Sponsor (as registered)
    Hudson Biotech
    Dates
    Start 2026-02-02 · record updated 2026-02-27

Glepaglutide 1 open study, 1 placebo-controlled

  • Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

    Recruiting NCT07197944 · Phase 3 · Randomized, quadruple-blind, vs placebo · 90 people

    Primary outcome
    Change in weekly Parenteral Support (PS) volume (Baseline to Week 24)
    Where
    Austria, Belgium, Denmark, Finland, France, Germany and 8 more
    Sponsor (as registered)
    Zealand Pharma
    Dates
    Start 2026-02-11 · record updated 2026-09-29

GLP-2 1 open study, 1 placebo-controlled

  • Postprandial Regulation of Bone Perfusion in Healthy Individuals

    Not yet recruiting NCT07679516 · No phase · Randomized, single-blind, vs placebo and an active drug · 15 people

    Primary outcome
    Median Ki in the Femur (90 minutes)
    Where
    Denmark
    Sponsor (as registered)
    University of Copenhagen
    Dates
    Start 2026-07-19 · record updated 2026-07-09

Gonadorelin 1 open study, 1 placebo-controlled

  • GnRH Therapy on Cognition in Down Syndrome

    Recruiting NCT04390646 · Phase 2 / Phase 3 · Randomized, triple-blind, vs placebo and an active drug · 56 people

    Primary outcome
    Cognition (Baseline to end of treatment (Week 24))
    Where
    Switzerland
    Sponsor (as registered)
    Nelly Pitteloud
    Dates
    Start 2020-08-27 · record updated 2024-02-12

    This registry record has not been updated since 2024-02-12, so its "recruiting" status may be out of date.

HM15275 1 open study, 1 placebo-controlled

  • Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

    Recruiting NCT07527650 · Phase 2 · Randomized, triple-blind, vs placebo · 180 people

    Primary outcome
    Change in Glycated Hemoglobin (HbA1c) (Up to 41 weeks)
    Where
    United States
    Sponsor (as registered)
    Hanmi Pharmaceutical Company Limited
    Dates
    Start 2026-05-18 · record updated 2026-10-19

Insulin detemir 1 open study

  • DETERMINE: Detemir vs NPH

    Recruiting NCT05124457 · Phase 2 · Randomized, open label, vs an active drug · 336 people

    Primary outcome
    Neonatal Hypoglycemia (Within the first 24 hours of life) +1 more
    Where
    United States
    Sponsor (as registered)
    University of California, Los Angeles
    Dates
    Start 2022-02-01 · record updated 2023-09-26

    This registry record has not been updated since 2023-09-26, so its "recruiting" status may be out of date.

LSALT peptide 1 open study, 1 placebo-controlled

Melanotan II 1 open study, 1 placebo-controlled

MK-677 1 open study, 1 placebo-controlled

  • Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

    Recruiting NCT06948214 · Phase 3 · Randomized, triple-blind, vs placebo · 150 people

    Primary outcome
    AHV after 12 months on LUM-201 compared to placebo (Day 1 to Month 12)
    Where
    Argentina, Australia, Chile, India, New Zealand, Thailand and 2 more
    Sponsor (as registered)
    Lumos Pharma
    Dates
    Start 2026-05-20 · record updated 2026-10-19

MOTS-c 1 open study, 1 placebo-controlled

Neuropeptide Y 1 open study

  • Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

    Recruiting NCT04838678 · Early phase 1 · Not randomized, open label, no comparator listed · 100 people

    Primary outcome
    Blood flow measured by doppler ultrasound (Acutely on the day of study) +1 more
    Where
    United States
    Sponsor (as registered)
    University of Texas Southwestern Medical Center
    Dates
    Start 2021-07-18 · record updated 2026-09-03

PACAP 1 open study, 1 placebo-controlled

Pancreatic polypeptide 1 open study, 1 placebo-controlled

Pemvidutide 1 open study, 1 placebo-controlled

Sonefpeglutide 1 open study, 1 placebo-controlled

Substance P 1 open study, 1 placebo-controlled

  • Substance P-Induced Migraine Attacks Without Aura

    Recruiting NCT06959004 · No phase · Randomized, quadruple-blind, vs placebo · 21 people

    Primary outcome
    Incidence of migraine attacks without aura (12 hours)
    Where
    Denmark
    Sponsor (as registered)
    Danish Headache Center
    Dates
    Start 2025-05-13 · record updated 2025-06-05

TB-500 1 open study, 1 placebo-controlled

VMT-α-NET 1 open study

  • Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

    Recruiting NCT05636618 · Phase 1 / Phase 2 · Not randomized, open label, no comparator listed · 300 people

    Primary outcome
    Number of participants with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT-α-NET (Incidence and severity of DLTs during the first 42 days of study treatment will be assessed.) +3 more
    Where
    United States
    Sponsor (as registered)
    Perspective Therapeutics
    Dates
    Start 2023-09-27 · record updated 2026-10-13

Zadavotide Guraxetan 1 open study

  • AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

    Recruiting NCT07611110 · Phase 3 · Randomized, single-blind, vs an active drug · 670 people

    Primary outcome
    Radiographic Progression-Free Survival (rPFS) (From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)) +1 more
    Where
    Australia, Austria, Belgium, Brazil, Canada, China and 18 more
    Sponsor (as registered)
    AstraZeneca
    Dates
    Start 2026-05-04 · record updated 2026-10-19

Zelenectide Pevedotin 1 open study

Zelpultide alfa 1 open study, 1 placebo-controlled

Approved abroad, or sold as a supplement (28)

Not FDA-approved, but approved in another country or sold as a supplement or diagnostic. Large programs show their 12 newest studies, with a link to the full list.

Melatonin 77 open studies, 48 placebo-controlled

Showing the 12 newest of 77. See all on ClinicalTrials.gov.

Mazdutide 21 open studies, 16 placebo-controlled

  • Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes

    Not yet recruiting NCT07924553 · No phase · Randomized, quadruple-blind, vs placebo · 182 people

    Primary outcome
    Proportion of the participants achieving time in range (TIR)>70 and time below range (TBR)<4% (TIMES-EFFICACY) (From baseline to 16 weeks) +1 more
    Where
    Not listed
    Sponsor (as registered)
    Peking University People's Hospital
    Dates
    Start 2027-01-01 · record updated 2026-11-09
  • Efficacy of Mazdutide on Fatty Pancreas

    Not yet recruiting NCT07803705 · No phase · Randomized, quadruple-blind, vs placebo · 194 people

    Primary outcome
    Percentage change in Intrapancreatic Fat Deposition (IPFD) from baseline (From baseline to Week 48)
    Where
    China
    Sponsor (as registered)
    Tongji Hospital
    Dates
    Start 2026-11-15 · record updated 2026-09-22
  • QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

    Recruiting NCT07775846 · Phase 4 · Randomized, quadruple-blind, vs placebo · 820 people

    Primary outcome
    Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6 (Baseline and Month 6)
    Where
    China
    Sponsor (as registered)
    Huijie Zhang
    Dates
    Start 2026-11-03 · record updated 2026-11-10
  • Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

    Not yet recruiting NCT07781150 · Phase 2 · Randomized, quadruple-blind, vs placebo · 128 people

    Primary outcome
    Complete response rate of endometrial lesions at 24 week (At 24 weeks after randomization)
    Where
    China
    Sponsor (as registered)
    Tongji Hospital
    Dates
    Start 2026-11-01 · record updated 2026-08-24
  • Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

    Not yet recruiting NCT07897305 · No phase · Randomized, single-blind, no comparator listed · 700 people

    Primary outcome
    Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs). (From enrollment to the end of treatment at 52 weeks) +1 more
    Where
    China
    Sponsor (as registered)
    Beijing Anzhen Hospital
    Dates
    Start 2026-10-25 · record updated 2026-10-27
  • A Study of HRS-4729 Injection in Participants With Type 2 Diabetes

    Not yet recruiting NCT07843862 · Phase 2 · Randomized, quadruple-blind, vs placebo and an active drug · 240 people

    Primary outcome
    Change From Baseline in HbA1c (Baseline, Week 28)
    Where
    China
    Sponsor (as registered)
    Fujian Shengdi Pharmaceutical Co., Ltd.
    Dates
    Start 2026-10 · record updated 2026-09-28
  • Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial

    Not yet recruiting NCT07767552 · No phase · Randomized, triple-blind, vs placebo · 249 people

    Primary outcome
    Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 44 (Baseline, 44 weeks)
    Where
    China
    Sponsor (as registered)
    Yanbing Li
    Dates
    Start 2026-09-30 · record updated 2026-08-17
  • Mazdutide for Weight Management and Gout in Adults With Obesity

    Not yet recruiting NCT07824895 · Phase 4 · Single group, open label, no comparator listed · 30 people

    Primary outcome
    Annualized Flare Rate (AFR) (Baseline to Week 52;Unit of Measure: Flares per person-year)
    Where
    Not listed
    Sponsor (as registered)
    Hongwei Jiang
    Dates
    Start 2026-09-15 · record updated 2026-09-17
  • Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

    Recruiting NCT07657676 · Phase 4 · Randomized, triple-blind, vs placebo · 116 people

    Primary outcome
    Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks (Baseline and 52 weeks)
    Where
    China
    Sponsor (as registered)
    China National Center for Cardiovascular Diseases
    Dates
    Start 2026-09-14 · record updated 2026-10-13
  • Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis

    Not yet recruiting NCT07797101 · No phase · Single group, open label, no comparator listed · 50 people

    Primary outcome
    Percentage Change in Hepatic Venous Pressure Gradient (HVPG) from Baseline (Baseline (screening, Day -14 to -1) to Week 16 (End of Treatment, Day 112 ± 3 days))
    Where
    Not listed
    Sponsor (as registered)
    The Second Affiliated Hospital of Chongqing Medical University
    Dates
    Start 2026-09-01 · record updated 2026-09-01
  • Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

    Recruiting NCT07718126 · Phase 4 · Randomized, quadruple-blind, vs placebo · 60 people

    Primary outcome
    Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM) (From randomization (Week 0) to Week 12)
    Where
    China
    Sponsor (as registered)
    West China Hospital
    Dates
    Start 2026-09-01 · record updated 2026-09-23
  • Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

    Not yet recruiting NCT07654062 · Phase 4 · Randomized, double-blind, vs placebo · 150 people

    Primary outcome
    Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24 (Week 24)
    Where
    China
    Sponsor (as registered)
    Shandong Provincial Hospital
    Dates
    Start 2026-07 · record updated 2026-06-17

Showing the 12 newest of 21. See all on ClinicalTrials.gov.

Carbetocin 12 open studies, 5 placebo-controlled

Recombinant Human Endostatin 8 open studies

Cerebrolysin 7 open studies, 4 placebo-controlled

Ecnoglutide 7 open studies, 7 placebo-controlled

Follitropin delta 6 open studies

  • Embryo QUAlity in Ovarian Stimulation With hMG.

    Not yet recruiting NCT07691073 · Phase 4 · Randomized, open label, vs an active drug · 240 people

    Primary outcome
    Good quality blastocysts (From Day 5 to Day 7 after insemination)
    Where
    Spain
    Sponsor (as registered)
    Fundacion Dexeus
    Dates
    Start 2026-09 · record updated 2026-07-08
  • Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

    Recruiting NCT07153367 · Phase 2 · Single group, open label, no comparator listed · 80 people

    Primary outcome
    Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation (up to 9 months)
    Where
    France
    Sponsor (as registered)
    Centre Hospitalier Intercommunal Creteil
    Dates
    Start 2025-12-17 · record updated 2026-04-08
  • Menopur And Rekovelle Combination Study Version 2.0

    Recruiting NCT06997900 · Phase 2 · Single group, open label, no comparator listed · 200 people

    Primary outcome
    number of good quality (>3BB) or utilizable blastocysts per treatment cycle at day 5 or 6 of embryo culture (5 to 6 days after egg retrieval (up to 1 to 2 months after enrollment))
    Where
    Canada
    Sponsor (as registered)
    Clinique Ovo
    Dates
    Start 2025-07-04 · record updated 2025-07-31
  • Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)

    Recruiting NCT07816562 · Phase 3 · Randomized, single-blind, no comparator listed · 126 people

    Primary outcome
    Number of mature oocytes (MII) (During the oocyte retrieval procedure)
    Where
    Spain
    Sponsor (as registered)
    Fundación para la Investigación del Hospital Clínico de Valencia
    Dates
    Start 2024-09-17 · record updated 2026-09-11
  • INtensity of OVarian Stimualtion and Euploid Embryos

    Recruiting NCT06154083 · Phase 4 · Randomized, open label, vs an active drug · 110 people

    Primary outcome
    Number of euploid embryos (Trough study completion, an average of 20-30 days.)
    Where
    Spain
    Sponsor (as registered)
    Fundación Santiago Dexeus Font
    Dates
    Start 2023-12-12 · record updated 2026-09-08
  • Real-world Evidence on Follitropin Delta Individual Dosing

    Recruiting NCT05173597 · No phase · Observational (no drug assigned by the study) · 850 people

    Primary outcome
    Ovarian response (2021-2022)
    Where
    Germany
    Sponsor (as registered)
    University of Luebeck
    Dates
    Start 2021-12-08 · record updated 2025-03-30

Efsubaglutide alfa 5 open studies, 4 placebo-controlled

  • Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

    Recruiting NCT07693426 · Phase 1 · Randomized, triple-blind, vs placebo · 36 people

    Primary outcome
    Safety and tolerability: incidence of TEAEs, SAEs, and AESI (Throughout the study (up to Week 18)) +1 more
    Where
    China
    Sponsor (as registered)
    Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
    Dates
    Start 2026-07-16 · record updated 2026-07-30
  • A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

    Not yet recruiting NCT07518121 · Phase 1 · Randomized, quadruple-blind, vs placebo · 48 people

    Primary outcome
    Maximum Observed Plasma Concentration (Cmax) of YN-011 (Predose through Day 29) +4 more
    Where
    Brazil
    Sponsor (as registered)
    Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
    Dates
    Start 2026-06-01 · record updated 2026-04-08
  • Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

    Recruiting NCT07163650 · Phase 4 · Randomized, quadruple-blind, vs placebo · 60 people

    Primary outcome
    Change in %TWL from baseline to endpoint (24 weeks from enrollment)
    Where
    China
    Sponsor (as registered)
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    Dates
    Start 2025-09-16 · record updated 2026-01-27
  • The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

    Recruiting NCT07114419 · Phase 2 · Randomized, quadruple-blind, vs placebo · 200 people

    Primary outcome
    Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks (22 weeks)
    Where
    Australia
    Sponsor (as registered)
    Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
    Dates
    Start 2025-08-25 · record updated 2025-12-02
  • Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

    Not yet recruiting NCT06900075 · Phase 3 · Randomized, open label, vs an active drug · 88 people

    Primary outcome
    Time in range (TIR) (6-8 weeks)
    Where
    Not listed
    Sponsor (as registered)
    Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
    Dates
    Start 2025-07-30 · record updated 2025-03-28

Teicoplanin 5 open studies

Collagen Peptides 4 open studies, 4 placebo-controlled

  • Effects of Different Collagen Formulations on Knee Osteoarthritis

    Not yet recruiting NCT07800780 · No phase · Randomized, quadruple-blind, vs placebo · 45 people

    Primary outcome
    Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score (Baseline (Week 0) and End of Intervention (Week 8))
    Where
    Turkey (Türkiye)
    Sponsor (as registered)
    Cihangir Türemiş
    Dates
    Start 2026-10-01 · record updated 2026-09-02
  • Dietary Supplements and Middle Aged Women (Collagen & Omega)

    Recruiting NCT07740967 · No phase · Randomized, triple-blind, vs placebo · 34 people

    Primary outcome
    Joint pain under 3 conditions as measured by a 100 mm visual analogue scale (VAS) (8 weeks)
    Where
    United Kingdom
    Sponsor (as registered)
    Loughborough University
    Dates
    Start 2026-05-01 · record updated 2026-08-03
  • Collagen Peptides and Cellular Aging

    Recruiting NCT07456449 · No phase · Randomized, quadruple-blind, vs placebo · 125 people

    Primary outcome
    Telomere length (Baseline and after supplementation (24 weeks)) +3 more
    Where
    Austria
    Sponsor (as registered)
    University of Vienna
    Dates
    Start 2026-04-22 · record updated 2026-05-05
  • CP: Intestinal Permeability

    Recruiting NCT07586930 · No phase · Randomized, quadruple-blind, vs placebo · 92 people

    Primary outcome
    Intestinal permeability (Day 42 to Day 45)
    Where
    Ireland
    Sponsor (as registered)
    Rousselot BVBA
    Dates
    Start 2026-03-25 · record updated 2026-05-27

Somatostatin 4 open studies

Sovateltide 4 open studies, 1 placebo-controlled

  • Sovateltide for the Treatment of Acute Traumatic Brain Injury

    Not yet recruiting NCT07861126 · Phase 3 · Randomized, quadruple-blind, vs placebo and an active drug · 214 people

    Primary outcome
    Proportion of patients achieving a favorable functional outcome (GOS-E score ≥7) at Day 90 post-randomization. Score range: 1 to 8; higher scores represent a better outcome. (90 days)
    Where
    Not listed
    Sponsor (as registered)
    Pharmazz, Inc.
    Dates
    Start 2026-12 · record updated 2026-10-13
  • Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

    Recruiting NCT05691244 · Phase 3 · Randomized, quadruple-blind, vs an active drug · 514 people

    Primary outcome
    Determine the efficacy of sovateltide in patients with acute cerebral ischemic stroke assessed by modified Rankin Scale (mRS) score of 0-2 at day 90 post-randomization. (Day 1 through Day 90)
    Where
    Australia, Germany, Spain, United Kingdom, United States
    Sponsor (as registered)
    Pharmazz, Inc.
    Dates
    Start 2025-07-24 · record updated 2026-11-13
  • Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

    Recruiting NCT05514340 · Phase 2 · Randomized, quadruple-blind, vs an active drug · 40 people

    Primary outcome
    Percentage of patients with death or disability (moderate/severe) (24 months)
    Where
    India
    Sponsor (as registered)
    Pharmazz, Inc.
    Dates
    Start 2023-09-06 · record updated 2025-12-31
  • PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

    Recruiting NCT04054414 · Phase 2 · Randomized, quadruple-blind, vs an active drug · 40 people

    Primary outcome
    Incidence of PMZ-1620 related adverse events (90 days) +1 more
    Where
    India
    Sponsor (as registered)
    Pharmazz, Inc.
    Dates
    Start 2019-01-10 · record updated 2025-07-04

Atosiban 3 open studies, 3 placebo-controlled

  • Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions

    Recruiting NCT07185230 · No phase · Randomized, triple-blind, vs placebo · 792 people

    Primary outcome
    Live birth (After 24 weeks of gestation)
    Where
    China
    Sponsor (as registered)
    Northwest Women's and Children's Hospital, Xi'an, Shaanxi
    Dates
    Start 2025-12-06 · record updated 2025-12-09
  • The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )

    Recruiting NCT07140237 · Early phase 1 · Not randomized, double-blind, vs placebo · 250 people

    Primary outcome
    Error rates in prosaccade and antisaccade trials (Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on numbers of prosaccade and antisaccade errors being collected continuously over a period of 35 minutes.) +1 more
    Where
    China
    Sponsor (as registered)
    University of Electronic Science and Technology of China
    Dates
    Start 2025-09 · record updated 2025-09-08
  • The Effect of Oral Oxytocin and Atosiban on Social Attention

    Recruiting NCT07093060 · Early phase 1 · Randomized, double-blind, vs placebo · 250 people

    Primary outcome
    Fixation duration (Fixation durations will be taken for each of the areas of interest in the four different visual paradigms starting 45 minutes post-treatment from the beginning of each paradigm until the end of each paradigm (each paradigm lasts around 10 minutes)) +1 more
    Where
    China
    Sponsor (as registered)
    University of Electronic Science and Technology of China
    Dates
    Start 2025-06-09 · record updated 2025-07-30

BNP 3 open studies, 2 placebo-controlled

  • rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)

    Not yet recruiting NCT07617675 · Phase 4 · Randomized, quadruple-blind, vs placebo · 694 people

    Primary outcome
    Incidence of acute kidney injury (AKI) within 7 days postoperatively, diagnosed per KDIGO criteria (Within 7 days after surgery, or until hospital discharge if earlier)
    Where
    China
    Sponsor (as registered)
    China National Center for Cardiovascular Diseases
    Dates
    Start 2026-05-01 · record updated 2026-06-01
  • Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

    Not yet recruiting NCT06745206 · No phase · Single group, open label, no comparator listed · 30 people

    Primary outcome
    The pressure gradient of venous return (From baseline to 30 minutes after rh-BNP initiation.)
    Where
    Not listed
    Sponsor (as registered)
    Sichuan Provincial People's Hospital
    Dates
    Start 2025-12 · record updated 2025-07-29
  • Nesiritide in Hypertension

    Recruiting NCT02608996 · Phase 1 / Phase 2 · Randomized, single-blind, vs placebo and an active drug · 15 people

    Primary outcome
    Changes in blood pressure (BP) (48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.)
    Where
    Norway
    Sponsor (as registered)
    Oslo University Hospital
    Dates
    Start 2015-12 · record updated 2018-01-03

    This registry record has not been updated since 2018-01-03, so its "recruiting" status may be out of date.

Pegmolesatide 3 open studies

PSMA-1007 3 open studies

  • Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

    Recruiting NCT06122584 · Phase 3 · Single group, open label, no comparator listed · 434 people

    Primary outcome
    Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference (6 to 8 weeks post-surgery)
    Where
    France, Germany, Italy, Japan, Netherlands, Spain
    Sponsor (as registered)
    ABX advanced biochemical compounds GmbH
    Dates
    Start 2024-06-13 · record updated 2026-11-04
  • The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

    By invitation NCT06723665 · No phase · Not randomized, open label, vs an active drug · 50 people

    Primary outcome
    18F-PSMA-1007 PET/CT and 18F-FDG PCT/CT imaging were compared to determine the advantages of 18F-PSMA-PSMA PET/CT imaging for prostate cancer (1 day)
    Where
    China
    Sponsor (as registered)
    Affiliated Hospital of Jiangnan University
    Dates
    Start 2024-01-25 · record updated 2025-01-24
  • 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

    Recruiting NCT05520255 · Phase 3 · Single group, open label, no comparator listed · 2,800 people

    Primary outcome
    Safety - immediate (Immediately after tracer injection) +3 more
    Where
    Canada
    Sponsor (as registered)
    University of Alberta
    Dates
    Start 2023-07-25 · record updated 2026-09-24

ANP 2 open studies, 1 placebo-controlled

Corifollitropin alfa 2 open studies

Emodepside 2 open studies, 1 placebo-controlled

Albuvirtide 1 open study

Aprotinin 1 open study, 1 placebo-controlled

  • Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment

    Recruiting NCT07317050 · Phase 3 · Randomized, double-blind, vs placebo · 156 people

    Primary outcome
    Ventilator-Free Days (VFD) in patients with moderate or severe ARDS (From first dose up to Day 28)
    Where
    Spain
    Sponsor (as registered)
    Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion
    Dates
    Start 2026-06-18 · record updated 2026-07-15

Beinaglutide 1 open study

Buserelin 1 open study

Carnosine 1 open study

  • Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

    Recruiting NCT06480760 · Phase 1 / Phase 2 · Randomized, triple-blind, no comparator listed · 120 people

    Primary outcome
    Measure distance covered on six-minute walk test (6MWT) (Baseline, 3 months, 6 months, 9 months)
    Where
    United States
    Sponsor (as registered)
    Shahid Baba
    Dates
    Start 2025-05-20 · record updated 2026-11-17

Mifamurtide 1 open study

Tertomotide 1 open study, 1 placebo-controlled

  • GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

    Not yet recruiting NCT05303701 · Phase 3 · Randomized, quadruple-blind, vs placebo · 750 people

    Primary outcome
    Change from baseline in SIB(Severe Impairment Battery) score after GV1001 administration for 24 weeks (Baseline, Week 26) +1 more
    Where
    Not listed
    Sponsor (as registered)
    Samsung Pharmaceutical Co., Ltd.
    Dates
    Start 2027-07 · record updated 2026-06-10

Testagen 1 open study

  • Product Transference Study of Testagen™ TDS®-Testosterone

    Not yet recruiting NCT02733133 · Phase 2 · Randomized, open label, no comparator listed · 96 people

    Primary outcome
    Transference of Topical Testosterone from Dosed Males to Female Partners As Measured by net change from Baseline of Serum Testosterone in nG/dL expressed as Maximum Serum Concentration or Cmax. (30 minutes to 24 hours post dose)
    Where
    Not listed
    Sponsor (as registered)
    Transdermal Delivery Solutions Corp
    Dates
    Start 2027-01-05 · record updated 2026-05-27

Thymosin α1 1 open study

Approved peptide drugs in new trials (106)

Drugs the FDA has already approved for something, now being tested for other uses, doses or combinations. One row each: how many open studies, how many are phase 3 or placebo-controlled, and a link to the full list on the registry.

DrugOpen studiesPhase 3Placebo-controlledNewest startRegistry
Semaglutide22551952028-10See them on ClinicalTrials.gov
Tirzepatide12720412027-12-12See them on ClinicalTrials.gov
Hyaluronic Acid939152027-01-01See them on ClinicalTrials.gov
Botulinum Toxin8325302027-01-01See them on ClinicalTrials.gov
Vancomycin7212122027-07See them on ClinicalTrials.gov
Oxytocin583342027-05-15See them on ClinicalTrials.gov
Cyclosporine44932026-12-01See them on ClinicalTrials.gov
Carfilzomib37802027-05-22See them on ClinicalTrials.gov
Leuprolide35922026-09-30See them on ClinicalTrials.gov
Goserelin34712026-10-20See them on ClinicalTrials.gov
Romiplostim30322026-11-01See them on ClinicalTrials.gov
Somatropin (HGH)25732027-01-01See them on ClinicalTrials.gov
Triptorelin251332026-10-14See them on ClinicalTrials.gov
Lutetium-177 DOTATATE24302026-10-11See them on ClinicalTrials.gov
Relugolix24812027-01-31See them on ClinicalTrials.gov
Vipivotide Tetraxetan24402027-01-06See them on ClinicalTrials.gov
HCG23642027-01-17See them on ClinicalTrials.gov
Bleomycin19712026-09-10See them on ClinicalTrials.gov
Erythropoietin (EPO)19632026-12-18See them on ClinicalTrials.gov
Vasopressin19662026-10-12See them on ClinicalTrials.gov
Colistin16532027-01-01See them on ClinicalTrials.gov
Gallium Ga 68 dotatate16002026-06-30See them on ClinicalTrials.gov
Octreotide16822027-01-01See them on ClinicalTrials.gov
Degarelix15432026-08-28See them on ClinicalTrials.gov
Liraglutide14142026-05-01See them on ClinicalTrials.gov
Desmopressin12452026-10-15See them on ClinicalTrials.gov
Insulin glargine12302026-11See them on ClinicalTrials.gov
Orforglipron12982026-12See them on ClinicalTrials.gov
Dulaglutide11422026-10See them on ClinicalTrials.gov
Sotatercept11112026-12-01See them on ClinicalTrials.gov
Angiotensin II10212026-11See them on ClinicalTrials.gov
Dactinomycin10502026-07-14See them on ClinicalTrials.gov
Insulin aspart10022026-11-02See them on ClinicalTrials.gov
Polymyxin B10102026-09-21See them on ClinicalTrials.gov
Glucagon9042027-01-01See them on ClinicalTrials.gov
Edotreotide8302025-09-26See them on ClinicalTrials.gov
Flotufolastat F 188002025-11-14See them on ClinicalTrials.gov
Gozetotide8102026-12-01See them on ClinicalTrials.gov
Insulin icodec8112027-01See them on ClinicalTrials.gov
Piflufolastat F 188002026-12See them on ClinicalTrials.gov
Teriparatide8112027-03-15See them on ClinicalTrials.gov
Pegcetacoplan7112027-01-21See them on ClinicalTrials.gov
Terlipressin7122026-09-25See them on ClinicalTrials.gov
Bivalirudin6002025-05See them on ClinicalTrials.gov
Bulevirtide6202026-02-26See them on ClinicalTrials.gov
Cetrorelix6202027-06-01See them on ClinicalTrials.gov
Follitropin alfa6102026-11See them on ClinicalTrials.gov
Insulin degludec6212026-11See them on ClinicalTrials.gov
Alprostadil5122028-01See them on ClinicalTrials.gov
Corticotropin5212026-09See them on ClinicalTrials.gov
Exenatide5002026-01-20See them on ClinicalTrials.gov
Voclosporin5112026-04-23See them on ClinicalTrials.gov
Zilucoplan5302026-01-20See them on ClinicalTrials.gov
Calcitonin4132026-07-01See them on ClinicalTrials.gov
Caspofungin4132026-09See them on ClinicalTrials.gov
Dalbavancin4202027-01-01See them on ClinicalTrials.gov
Lanreotide4212025-06-12See them on ClinicalTrials.gov
Lixisenatide4002026-03-15See them on ClinicalTrials.gov
Metreleptin4112024-10-14See them on ClinicalTrials.gov
Motixafortide4002026-07-23See them on ClinicalTrials.gov
Nafarelin4102026-10-14See them on ClinicalTrials.gov
Palopegteriparatide4202026-05-07See them on ClinicalTrials.gov
Secretin4102025-04-26See them on ClinicalTrials.gov
Somapacitan4002024-12-13See them on ClinicalTrials.gov
Vosoritide4222026-04-20See them on ClinicalTrials.gov
Elamipretide3012026-11See them on ClinicalTrials.gov
Enlicitide3232026-10-15See them on ClinicalTrials.gov
Ganirelix3002026-09See them on ClinicalTrials.gov
Insulin lispro3012025-12-11See them on ClinicalTrials.gov
Linaclotide3032026-09See them on ClinicalTrials.gov
Navepegritide3232026-11See them on ClinicalTrials.gov
Pasireotide3102025-05-30See them on ClinicalTrials.gov
Romidepsin3002025-06-24See them on ClinicalTrials.gov
Setmelanotide3112026-07-21See them on ClinicalTrials.gov
Somatrogon3102026-11See them on ClinicalTrials.gov
Tesamorelin3022026-02-02See them on ClinicalTrials.gov
Ziconotide3002026-05-02See them on ClinicalTrials.gov
Abaloparatide2002026-06-18See them on ClinicalTrials.gov
Apitegromab2012026-07-30See them on ClinicalTrials.gov
Daptomycin2002024-11-14See them on ClinicalTrials.gov
Difelikefalin2012026-08-04See them on ClinicalTrials.gov
Elagolix2012026-05-01See them on ClinicalTrials.gov
Etelcalcetide2202019-12-20See them on ClinicalTrials.gov
Follitropin beta2002025-07-08See them on ClinicalTrials.gov
Glatiramer Acetate2102026-06-15See them on ClinicalTrials.gov
Histrelin2102024-06-03See them on ClinicalTrials.gov
Insulin glargine / lixisenatide (iGlarLixi)2002025-12-13See them on ClinicalTrials.gov
Lonapegsomatropin2212026-11See them on ClinicalTrials.gov
Oritavancin2002026-07-01See them on ClinicalTrials.gov
Regular human insulin2022026-02-20See them on ClinicalTrials.gov
Rezafungin2102025-10-15See them on ClinicalTrials.gov
Rusfertide2002027-03-01See them on ClinicalTrials.gov
Teduglutide2002026-07-01See them on ClinicalTrials.gov
Tetracosactide2002021-11-01See them on ClinicalTrials.gov
Thyrotropin alfa2002024-07-15See them on ClinicalTrials.gov
Bacitracin1002026-04-01See them on ClinicalTrials.gov
Copper Cu 64 dotatate1002024-05-31See them on ClinicalTrials.gov
Eptifibatide1102026-03-01See them on ClinicalTrials.gov
Garetosmab1102027-02-02See them on ClinicalTrials.gov
Gramicidin1002024-12-10See them on ClinicalTrials.gov
Icotrokinra1112025-10-03See them on ClinicalTrials.gov
IGF-11012019-09-06See them on ClinicalTrials.gov
Mecasermin1002008-12-09See them on ClinicalTrials.gov
Pegvisomant1002023-01-23See them on ClinicalTrials.gov
Telavancin1002024-07-02See them on ClinicalTrials.gov
Trofinetide1002026-08-01See them on ClinicalTrials.gov
How this list is made

For each of the 416 encyclopedia peptides that have any registered trial, we ask ClinicalTrials.gov (API version 2) for studies whose status is recruiting, not yet recruiting, or enrolling by invitation, searching by intervention name. The registry's search is fuzzy, so a study is kept only if the peptide's name or one of its recorded aliases is listed as an intervention the study gives (a drug, biologic, supplement or radiopharmaceutical), and not as part of another thing's name: a "GLP-1 receptor agonist", a "CGRP antibody" or a "BNP level" is not native GLP-1, CGRP or BNP. "Compared with" reads the study's arm types and intervention names: a placebo or sham arm counts as placebo, an active-comparator arm as an active drug. Sponsor names are shown as the sponsor registered them; listing a sponsor is not an endorsement, and the registry does not check that a sponsor's product is what it says. A record its sponsor has not updated in 2 years is flagged, because the registry's status is only as current as the sponsor keeps it. A failed registry request is recorded as an error and blocks the page from rebuilding, so an outage is never shown as "no trials". The list is re-read at least every 45 days. See the trials and outcomes tracker for how far each peptide got, including the ones that failed.